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ABSTRACT
Objectives: To assess associations between the
launch of the National Dementia Strategy (NDS) and
antipsychotic prescribing in long-term residential care
(LTC) in England.
Setting and participants: Retrospective analysis of
prescribing patterns in 616 LTC institutions (31 619
residents) following launch of the NDS, using
information from electronic medicines management
system.
Primary and secondary outcome measures:
Antipsychotic prescribing point prevalence (PP) for
all residents in a cross section of LTC settings over a
4-year period following NDS launch. Secondary
outcomes included dosages, length of treatment and
use of recommended second-generation antipsychotics
(SGAs) versus first-generation antipsychotics (FGAs).
Associations between facility-level PP values and
institutional characteristics, resident demographics
were explored. Variations across geographical areas
examined. Prescription net ingredient costs calculated.
Results: No statistically significant difference was
observed in overall prescribing rates over the 4-year
period (Kolmogorov-Smirnov (KS) test p=0.60), and
there was no significant shift towards newer SGAs (KS
test p=0.32). Dosages were above the maximum
indicated in only 1.3% of cases, but duration of
prescribing was excessive in 69.7% of cases. Care
homes in the highest prescribing quintile were more
likely to be located in a deprived area (rate ratio (Q5/
Q1) RR=5.89, 95% CI 4.35 to 7.99), registered for
dementia (RR=3.38, 95% CI 3.06 to 3.73) and those in
the lowest quintile were more likely to be served by a
single general practitioner (GP) practice (RR=0.48;
95% CI 0.37 to 0.63); p<0.001 all. A sixfold variation
in PP levels was observed between geographical areas.
The average annual expenditure on antipsychotics was
£65.6 per person resident (2012 prices).
Conclusions: The NDS in England was not associated
with reduced PP levels or the types of antipsychotic
prescribing in care homes. Further research is needed
to explore why. Clear standards specifying
recommended agents, dosages and length of
treatment, together with routine monitoring and greater
accountability for antipsychotic prescribing, may be
required.
INTRODUCTION
There continues to be considerable inter-
national debate about the optimum care of
older people with dementia, especially those
living in care homes.1–4 In England, it is esti-
mated that 46% of new admissions to care
homes are for reasons of dementia5 and
more than one-third of people with demen-
tia (36.5%) now live in care homes.6 For anti-
psychotics, which were originally developed
for use in patients with schizophrenia or
psychosis, there is evidence of ‘off-label’ pre-
scribing of unlicensed medicines for behav-
ioural and psychological symptoms in
dementia (BPSD).4 7
Strengths and limitations of this study
▪ To our knowledge, this is the first UK study to
examine long-term impact of a national policy
initiative on antipsychotic prescribing in care
homes. The samples studied are many times
those of other UK antipsychotic usage studies.
▪ Prescribing rates, antipsychotic agent type
(including unlicensed antipsychotics) and length
of treatment were unchanged.
▪ The factors preventing sustained change in anti-
psychotic prescribing and regional variations
observed remain unclear.
▪ One limitation of this observational study is the
lack of comparable national data to demonstrate
representativeness of the study sample.
▪ A further limitation of this study is the lack of
clinical and staffing data to complement the
detailed prescription data.
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In the 1990s, calls in the USA for control of the use of
ﬁrst-generation antipsychotics (FGA) for BPSD led to
the Omnibus Budget Reconciliation Act (OBRA) which
introduced regulation stipulating recommended dosages
for their use in nursing homes.8 9 In the UK, thiorida-
zine (trade name Melleril), a commonly used FGA, was
banned in 2008 following evidence of cardiac toxicity
and limited effectiveness.10 Prior to its ban, thioridazine
was the most commonly prescribed antipsychotic in UK
long-term residential care (LTC), accounting for 51–
74% of prescriptions.11 12 With the introduction of
second-generation antipsychotics (SGAs),13 concerns
continued to be raised in the UK and the USA about
their use for BPSD treatment.14 15 In the USA, no anti-
psychotic has been approved to date by the Food and
Drug Administration for BPSD.16 In the UK, the
Medicines & Healthcare products Regulatory Agency
has licensed only one antipsychotic (risperidone), for
short-term BPSD treatment (up to 6 weeks) and for per-
sistent aggression.17 Australia and Canada have similarly
only approved risperidone.18 19 In most countries, there-
fore, use of other antipsychotics remains unlicensed or
off-label.20 It has recently been argued that widespread
off-label prescribing for BPSD requires regulatory inter-
vention to safeguard vulnerable older people.21
Inappropriate prescribing of antipsychotic medication
is recognised as a marker of poor care,3 22 especially if
prescriptions are not regularly reviewed by the prescrib-
ing physician.23 Although the principle of protecting
older people’s human rights when they cannot consent
to treatment is well developed with respect to the use of
physical restraints and deprivation of liberty, it is
acknowledged that protection against inappropriate use
of ‘chemical restraints’ is less well developed.24 To date,
controlled trials have demonstrated limited clinical efﬁ-
cacy for use of antipsychotics in BPSD, with only small
effect sizes reported on global behavioural disturb-
ance.25 Long-term use of antipsychotic drugs is also asso-
ciated with increasing concerns about serious adverse
effects including mortality.26 The European Federation
of Neurological Societies task force recommended in
2007 that all antipsychotics be used with caution in
elderly patients with dementia, although no speciﬁc
guidance was provided on dosage or length of
treatment.27
In 2009, the UK Department of Health commissioned
a policy review on antipsychotic use in dementia. The
resulting report concluded that usage was unacceptably
high and recommended a two-thirds reduction over a
period of 3 years as a target.20 The UK Royal College of
Psychiatrists conﬁrmed that older people could safely be
withdrawn from agents like risperidone over a 2–4-week
period with no adverse consequences.28 29 This policy
review also stipulated that SGA agents should be pre-
scribed in preference to FGA agents; that the lowest pos-
sible effective dose should be prescribed for the shortest
period (ideally <12 weeks); and that treatment should
be reviewed at least monthly with reduction or cessation
actively considered at each review.20 Similar recommen-
dations were incorporated as guidelines in a National
Dementia Strategy (NDS) launched in February
2009.30 31
In England, the majority of care home residents
(60%) are in residential homes typically with no on-site
nursing staff.32 33 Although general practitioners (GPs)
prescribe and are responsible for monitoring medication
in care homes, medicines management (ordering,
administering) is undertaken by social care staff who
may have no formal training in medication practice.34 In
the USA, administration of antipsychotic treatment by
untrained staff unaware of safety issues is reported to
have been a contributory pressure leading to the OBRA
initiative.
In this paper, we report the ﬁndings of a large-scale
study in England that examines antipsychotic prescrib-
ing in nursing and residential homes following the intro-
duction of the NDS. To date, the UK research on
medication use in care homes remains limited,35–37 with
no large-scale studies of antipsychotic prescribing levels
generally or long-term impact of the NDS. Our research
investigated whether prescribing levels changed over the
4 years following introduction of the NDS guidance; the
degree to which recommendations in terms of the types
of agents prescribed and the length of treatment have
been achieved; and variations in the patterns of prescrib-
ing between different institutions and geographical
areas.
OBJECTIVES
▸ To assess whether the implementation of the NDS
was associated with a decrease in prescribing of anti-
psychotics in LTC and, where prescribed, a shift
towards newer SGAs.
▸ To examine differences in prescribing patterns
between LTC institutions and different geographical
areas, including the agents prescribed, dosages and
length of exposure (LOE).
▸ To explore the characteristics of high/low prescribing
LTC institutions.
▸ To consider the potential use of data on prescribing
in UK LTC.
METHODS
Overview and data preparation
Prescription data were provided via a double-barcode
electronic medicines management (EMM) system
designed for care homes (see online supplementary
ﬁle 1). This source had previously been used to examine
drug administration patterns in care homes (see online
supplementary ﬁle 2).35 Data were downloaded by the
company for all care homes with the EMM system for
the period 2009–2012, downloaded in two separate
anonymised ﬁles and merged for analysis. The ﬁrst con-
tained details of all antipsychotic prescriptions, and the
second de-identiﬁed resident data and anonymised LTC
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characteristics. Data were analysed at two time points: 1
January 2009 (prior to NDS launch) and 31 December
2012 (4 years post-NDS). For each time point, a com-
plete data set was examined to include all residents,
there were no exclusions. Because the number of care
homes which had implemented the EMM system
increased over this period, a data subset was extracted
for a cohort of care homes with the EMM system in
place throughout the 4-year period (Cohort C). The
National Research Ethics Service, National Patient Safety
Agency, London W1T 5HD approved this retrospective
study, which was designated a service evaluation (refer-
ence number 04/02 28 October 2009).
For each prescription, dosage was converted to an
equivalent daily dose in milligram; administration
format was classiﬁed as tablet, liquid or injection; trade
names were recoded to a common single British
National Formulary (BNF) name.38 All non-risperidone
use was deﬁned as off-label. Care homes were charac-
terised in terms of following: type of institution (eg,
nursing, residential home); registration status (eg, regis-
tered for ‘dementia’ or ‘old age only’); number of beds;
any self-declared specialism (eg, Alzheimer’s care); and
geographical location.
Dosages were compared with an ‘indicative’ maximum
daily dosage (IDD), predeﬁned for each agent. Three
different sources were used in turn, since there is no
comprehensive UK guidance on IDD levels for older
people. First, if the BNF contained a recommended
dose for ‘agitation and restlessness’ in older people or
less speciﬁcally for ‘elderly patients’ this was used as
‘best available’ evidence. Second, if the US OBRA
recommendations speciﬁed a maximum dosage, this was
used.8 9 Finally, for all other agents the upper dosage
reported in a UK survey of hospital specialists in old age
psychiatry for dementia was used.39 The LOE was esti-
mated by summing repeat antipsychotic prescriptions
for each individual resident until the ﬁnal prescription;
due to the time-consuming nature of this process, such
analysis was limited to the licensed agent (risperidone).
Measurements
We calculated the following:
▸ Prescribing levels in terms of point prevalence (PP)
that is, the percentage of residents prescribed at least
one antipsychotic at each time point.
▸ For each prescription, the observed daily dosage
classiﬁed in terms of IDD for that agent. Dosage was
categorised as ‘recommended’ (≤IDD), ‘high’ (>100–
200% IDD) or ‘excessive’ (>200% IDD). Cases of pro
re nata (PRN) or ‘as needed’ prescribing were
recorded separately.
▸ LOE values were compared with the recommended
6 weeks17 and 12 week maximum.20 30 LOE was cate-
gorised as ‘recommended’ (≤6 weeks treatment),
‘acceptable’ (>6 to <12 weeks) or ‘excessive’
(≥12 weeks).
▸ Net ingredient cost of each antipsychotic prescrip-
tion, excluding any dispensing costs or fees, was esti-
mated using BNF unit prices (accessed 6 December
2012).
▸ Primary medical support was categorised in terms of
the number of GP practices, serving an LTC facility
plus the size of these practices (ie, number of
doctors). An additional proxy measure of quality was
whether these included a teaching practice.
▸ LTC neighbourhoods were classiﬁed as ‘deprived’ or
‘non-deprived’, with deprived deﬁned as a neighbour-
hood in the top 10% of Index of Multiple
Deprivation scores nationally.40
▸ Each LTC was linked to the body responsible for
health services in its geographical area (ie, Primary
Care Trusts (PCTs) at this time); PCTs were cotermin-
ous with local government authorities responsible for
provision of LTC social care services.41
Statistical analysis
A comparative descriptive design was adopted compar-
ing cross-sectional and longitudinal data. Numerical
data were summarised using mean and SD or median
and range depending on data distribution. Stata (V.12)
was used for all analyses.
Sample descriptors and prescribing patterns
Prescribing patterns were analysed to include PP levels
for all antipsychotics and for FGAs / SGAs separately,
dosages in terms of IDD levels and LOE for risperidone.
The mean annual expenditure on antipsychotics per resi-
dent was estimated by summing the cost of all prescrip-
tions in an LTC setting and dividing by the total number
of residents; costs were adjusted to 2012 prices.42
Trend in prescribing
Cumulative distribution plots of PP values were pro-
duced for all antipsychotics and separately for FGA and
SGA agents. The two-sample Kolmogorov-Smirnov non-
parametric statistical test (KS2-test) was used to compare
distributions at baseline and 48 months.43 Plots for the
common subset (Cohort C) were similarly compared.
Characteristics of high/low prescribing institutions
Care homes were placed into quintiles based on their
baseline PP level; if an organisation was placed in a par-
ticular quintile, all residents in that home were placed in
the same quintile. Quintiles were compared for categor-
ical variables (ie, resident demographics and care home
characteristics). Rate ratios were derived for the ﬁfth
quintile divided by the ﬁrst quintile and 95% CI limits
reported using a δ-method SE.
Geographical variations
For each PCT area, the mean prescribing level (PP value
across all care homes), ratio of SGA:FGA prescriptions
and the proportion of off-label (ie, non-risperidone)
prescriptions were estimated. For risperidone, the
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proportion of cases in which this was the ﬁrst-line
therapy was calculated, together with PP values for
risperidone.
RESULTS
Sample descriptors
Table 1 shows details of baseline and 48-month samples.
The mean age of residents was 83.7 years (baseline) and
78.8 years (48 months), and the majority were female
(71.9% vs 68.0%). Cohort C demonstrated a similar
age/gender breakdown. At baseline, 55% of care homes
operated in a ‘multipractice’ context (served by ≥4 GP
practices), with only 13.7% served by a single GP prac-
tice; 24% had access to at least one teaching GP prac-
tice. Number of GP practices was not related to care
home size, so in the multipractice model individual GP
practices were caring for 3–13 residents versus 30–41
patients in the single practice model. A total of 48% of
care homes were registered for dementia and the
remainder for ‘old age only’.
Pattern of antipsychotic agents prescribed
Table 2 provides a detailed breakdown of antipsychotic
prescribing over the 48-month period. This shows that
mean PP rates did not reduce signiﬁcantly; 18% at base-
line versus 19% at 48 months post-NDS. Further analysis
indicates that nursing and residential homes exhibit
similar PP rates; 17.3% and 18.6% respectively at base-
line, and 21.0% and 19.2% at 48 months. SGAs are the
most frequently used agents (68% of all prescriptions),
as recommended in the NDS, with no signiﬁcant differ-
ences between nursing and residential homes. Similar
patterns are observed in Cohort C. FGA agents are pre-
scribed less often than SGAs, with haloperidol the most
commonly used. Although six residents were still pre-
scribed the banned FGA thioridazine at baseline, by
2012 this ﬁgure had fallen to zero.
Residents were very rarely (0.7% at baseline and
1.67% at 48 months) prescribed more than one anti-
psychotic at the same time. Most antipsychotics were
administered in tablet form (82%) with 17% as an oral
liquid. The average annual expenditure on antipsycho-
tics was £65.6 per person resident (2012 prices).
Expenditure was slightly higher in nursing homes
(£71.0) than residential homes (£60.4).
The vast majority of treatments at baseline (82%) were
above the recommended 6 weeks; at the end of 2012,
this ﬁgure had risen to 87.3%, with 69.7% and 77.6%,
respectively, above 12 weeks. In contrast, dosages were
within IDD levels in 98.7% of cases at baseline; PRN pre-
scriptions were extremely rare (<1%).
Trends in prescribing
Figure 1 displays cumulative distribution PP plots at base-
line and 48 months post-NDS for all care homes
(ﬁgure 1A) and separately for Cohort C (ﬁgure 1B).
No statistically signiﬁcant decreases were observed for
either (KS test p=0.60 and p=0.74, respectively). For
SGAs and FGAs separately, a similar analysis indicates no
signiﬁcant shift towards newer SGAs (KS test p=0.32) or
away from FGAs (KS test p=0.26).
Table 1 Care home and resident characteristics
Total Cohort C
Sample characteristics
Baseline (1
January 2009)
Month 48 (31
December 2012)
Baseline (1
January 2009)
Month 48 (31
December 2012)
Number of homes 211 616 166 166
Number of residents 8357 31 619 6979 9006
Resident demographics
Women, % 71.9 68.0 71.9 69.1
Age years (mean) 83.7 78.8 83.8 80.1
65–74 years, % 8.9 16.9 8.8 14.4
75–84 years, % 34.8 44.5 34.8 45.5
85 years and over, % 52.5 30.3 52.8 34.0
Care home characteristics
Mean size (number of
residents)
39.6 51.3 42.0 54.3
Median size (IQR) 37 (18) 46 (30) 39 (19) 49 (28)
Type of home (% all homes)
Residential home, % 47.9 25.8 48.8 48.2
Nursing home, % 39.3 23.5 39.2 34.9
Dual registered*, % 12.8 50.7 12.1 16.9
Medical support (% all homes)
1 GP practice, % 13.7 11.0 11.5 8.4
2–3 GP practices, % 31.3 29.7 31.9 29.5
4+ GP practices, % 55.0 59.3 56.6 62.1
*Providing nursing and residential care.
GP, general practitioner.
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Characteristics of high/low prescribing institutions
Table 3 presents the characteristics of residents and LTC
institutions in the highest and lowest prescribing quin-
tiles. In terms of care home characteristics, size and type
of institution (nursing or residential) show no clear dif-
ferences. However, the highest quintile is more likely to
include residents in institutions situated in a deprived
neighbourhood (rate ratio (Q5/Q1) RR=5.89, 95% CI
4.35 to 7.99), those in homes registered for dementia
(RR=3.38, 95% CI 3.06 to 3.73), or residents in homes
served by four or more GP practices (RR=1.38; 95% CI
1.30 to 1.46). In terms of resident characteristics, older
residents aged 85 years plus were less likely to be in the
upper quintile (RR=0.63, 95% CI 0.58 to 0.68) and
younger residents aged 65–74 more likely (RR=1.75,
95% CI 1.41 to 2.17). Those aged 75–84 years have a
95% CI which does not overlap with the other two
groups, suggesting they are more likely to be in the
upper quintile than those aged 85 plus, but less likely
than those aged 65–74. There was a slight gender differ-
ence (females RR=0.86, 95% CI 0.82 to 0.90).
Geographical variations
Table 4 presents PCT-level data for the 26 geographical
areas in which care homes are located. PCTareas, arranged
in order of decreasing PP rates, demonstrate a sixfold
Table 2 Breakdown of antipsychotic prescribing patterns
Total Cohort C
Prescribing
Baseline (1 January
2009)
Month 48 (31 December
2012)
Baseline (1 January
2009)
Month 48 (31 December
2012)
PP, %
All antipsychotics
Mean (SD) 18.0 (±12.0) 19.0 (±15.2) 18.3 (±11.9) 18.0 (±12.3)
Median (IQR) 15.2 (11.8) 15.4 (14.0) 15.3 (11.4) 15.1 (12.7)
SGAs
All SGAs 12.5 14.6 12.8 13.9
Quetiapine 5.1 4.7 4.9 3.9
Risperidone 4.0 5.3 4.2 6.4
Olanzapine 2.1 3.0 2.3 2.9
FGAs
All FGAs 5.9 5.4 5.8 5.2
Haloperidol 2.5 3.0 2.3 2.4
Daily dosage, %*
Recommended 98.7 NA 98.6 NA
High 0.3 NA 0.3 NA
Excessive 1.0 NA 1.1 NA
Length of exposure, %†
Recommended 18.0 12.8 18.2 10.2
Acceptable 12.3 9.7 12.2 6.4
Excessive 69.7 77.6 69.7 83.5
*Percentage of total prescriptions with following daily dosage: ‘recommended’ ≤ maximum IDD; ‘high’ >100–200% IDD; ‘excessive’ >200% IDD.
†Percentage of risperidone prescriptions with following LOE: ‘recommended’ ≤6 weeks; ‘acceptable’ >6 to <12 weeks; ‘excessive’ ≥12 weeks.
FGAs, first-generation antipsychotics; IDD, indicative maximum daily dosage; LOE, length of exposure; NA, not applicable; PP, point prevalence;
SGAs, second-generation antipsychotics.
Figure 1 Cumulative distribution plots of prescribing point prevalence values care homes at 1 January 2009 (baseline) and
31 December 2012 (48 months) for all antipsychotics.
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variation in prescribing level between 5.7% and 37.5%
(overall mean 17.6%). The proportion of prescriptions for
SGAs similarly shows an eightfold difference, ranging
between 11.1% and 89.5% (mean 62.9%), with SGA use
unrelated to overall PP value. Rates of off-label (non-
risperidone) prescribing vary between 5.4% and 31.3%
(mean 13.9%). For risperidone, an overall PP value of
3.7% masks large geographical differences (range 0–
6.2%). Detailed analysis of risperidone prescriptions also
indicates that, although this was the ﬁrst-line treatment in
75.2% of cases when prescribed, this ﬁgure varies between
0% and 100% in individual PCTs as shown in the ﬁnal
column.
DISCUSSION
This study has used data on many more care home resi-
dents than any similar UK study. This shows that reduc-
tions in the prescribing of antipsychotics driven by the
NDS have not been sustained in care homes.
Furthermore, we demonstrate that contrary to guidance,
older antipsychotic agents are still being used extensively
rather than safer SGAs. We observed that most residents
were prescribed antipsychotics within acceptable
dosages; however, in the majority of cases, length of
treatment was excessive. These results differ from an
analysis of UK GP practice records over 16 years which
identiﬁed a fall in levels of prescribing of antipsychotics
at the point when dementia is ﬁrst recorded, from
19.9% in 1995 to 7.4% in 2011.44 A recent study in
England found that the launch of the NDS was linked to
an increase in diagnosis rates and prescriptions for anti-
dementia medications from 2006/2007 to 2011/2012.45
A trend towards earlier diagnosis may explain the fall in
antipsychotic prescribing reported in 2011 in the ﬁrst
study.44 Neither study provided separate ﬁgures for care
homes. In the USA, differences in prescribing rates in
nursing homes before and after the introduction of
OBRA have been reported.46
English studies of antipsychotic prescribing levels in
care homes are limited, usually based on small samples
(<1000 people), typically undertaken in a single geo-
graphical area.20 Even so, similar rates to those found in
our study have been reported; 17.8% for residential and
21.9% for nursing homes in a single-region study,47 20%
for a single-city study in 65 care homes4 and 24.5% in a
Table 3 Care homes in high and low prescribing quintiles (baseline sample)
Quintile RR (95% CI)
Care home characteristics Total population Q1 (lowest) Q5 (highest) Q5/Q1
Home type
Residential home—n (%) 3703 (44.3) 831 (46.3) 737 (51.5) 1.11 (1.04 to 1.19)
Nursing home—n (%) 3422 (41.0) 682 (38.0) 561 (39.2) 1.03 (0.95 to 1.13)
Dual registered—n (%) 1232 (14.7) 282 (15.7) 133 (9.3) 0.59 (0.49 to 0.72)
All p<0.001
Registered for dementia 3359 (48.0) 335 (22.3) 913 (75.4) 3.38 (3.06 to 3.73)
Registered for old age, not dementia 3644 (52.0) 1168 (77.7) 298 (24.6) 0.32 (0.29 to 0.35)
All p<0.001
Area deprivation
Deprived neighbourhood—n (%) 459 (6.1) 48 (2.9) 219 (17.1) 5.89 (4.35 to 7.99)
Non-deprived neighbourhood—n (%) 7089 (93.9) 1598 (97.1) 1059 (82.9) 0.85 (0.83 to 0.88)
All p<0.001
Practices serving home
1 GP practice—n (%) 866 (10.4) 180 (10.0) 68(4.8) 0.48 (0.37 to 0.63)
2–3 GP practices—n (%) 3011 (36.0) 729 (40.6) 387(27.0) 0.67 (0.60 to 0.74)
>4 GP practices—n (%) 4480 (53.6) 886 (49.4) 976 (68.2) 1.38 (1.30 to 1.46)
All p<0.001
Care home size*
Small—n (%) 545 (6.5) 183 (10.2) 95 (6.6) 0.65 (0.51 to 0.82)
Medium—n (%) 2887 (34.6) 554 (30.9) 643(44.9) 1.45 (1.33 to 1.59)
Large—n (%) 4925 (58.9) 1058 (58.9) 693(48.5) 0.82 (0.77 to 0.88)
All p<0.001
Age/gender of residents 8357 1795 1431
Women—n (%) 6011 (71.8) 1343 (74.8) 922 (64.4) 0.86 (0.82 to 0.90)
Age 65–74—n (%) 744 (8.9) 129 (7.2) 181 (12.6) 1.75 (1.41 to 2.17)
Age 75–84—n (%) 2911 (34.8) 554 (30.9) 564 (39.4) 1.28 (1.16 to 1.40)
Age >85—n (%) 4392 (52.5) 1071 (59.7) 536 (37.5) 0.63 (0.58 to 0.68)
All p<0.001
p Values in the RR column are from Pearson’s χ2 test of associated between the characteristic variable and the first and fifth quintile indicator.
*Small ≤24 residents; medium 25–39 residents; large ≥40 residents.
GP, general practitioner; NA, not applicable; RR, Rate ratio.
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single-region study among 934 residents.12 Elsewhere, it
has been suggested that up to 27% of UK care home
residents may be receiving antipsychotics.48 More
recently, a survey of care home managers in the East of
England identiﬁed a rate of 12%; this was self-reported
by 299/737 managers, so response bias cannot be ruled
out.49 Internationally, US rates appear to be slightly
higher, although studies are limited to nursing homes.50
Rates of 27.6% in 2000–2001,2 3 8% in 20053 and 25%
in 201151 have been reported for large-scale population
samples. In contrast to these US ﬁgures, which are based
on 2–3 million Medicare beneﬁciaries, smaller scale
studies in other parts of the world generally report
higher levels of antipsychotic use.46 Reported rates in
2005–2006 include 30.3% and 36.9% in two Canadian
LTC facilities,52 25.1% in 40 Australian nursing homes18
and 39–42% in 41 institutions in Finland.53 The rates
observed in our study are therefore comparatively low.
Although we found no decrease in overall prescribing
levels, it is also important to consider why we observed
no shift towards SGAs, why off-label prescribing
remained high and why length of treatment continued
to exceed the recommended 6–12 weeks (although
dosages were within an acceptable range). A comparable
2005 analysis of data for US nursing home residents
found 73.5% were receiving SGAs, 13.4% FGAs and
13.04% both.3 In our study, the proportion of SGAs was
similar at 69%, but <2% residents were prescribed more
than one agent. In Australia, a much lower level (40%)
of SGA use has been reported in a cohort study of 2005
residents.54 In our baseline cohort, the most commonly
prescribed SGAs were quetiapine, risperidone and olan-
zapine. This is similar to self-reported preferences in a
survey of UK hospital specialists in old age psychiatry.39
In terms of dosage levels, there is no other recent UK
evidence available. However, a US study found that
17.2% of 1096 nursing home residents were prescribed
antipsychotic doses (excluding PRN) that exceeded
maximum levels.3 Our study indicates a lower level of
1.3% in England. Our ﬁndings also conﬁrm that off-
label prescribing continues to be a problem. In March
2012, the US Centers for Medicare and Medicaid
Services launched a quality initiative that recommended
a 15% decrease in off-label prescribing of unlicensed
antipsychotics in nursing homes over 9 months.55 No
similar quality initiative has been launched in the UK.
Table 4 Prescribing patterns by geographical area (baseline sample)
PCT area
Prescribing patterns
Antipsychotic prescriptions
Risperidone
prescriptions
Point
prevalence all (%)
Proportion
SGA agents (%)
Point prevalence
off-label prescribing (%)
Point
prevalence (%)
Percentage which are
first-line prescriptions
Area 1 37.5 11.1 31.3 6.2 0
Area 2 24.8 49.4 22.7 2.1 83.3
Area 3 24.3 33.3 21.6 2.7 100.0
Area 4 24.1 89.4 20.0 4.1 81.8
Area 5 23.5 67.8 21.0 2.5 90.0
Area 6 22.0 66.7 16.0 6.0 100.0
Area 7 20.9 60.6 19.2 1.7 87.5
Area 8 20.6 37.7 18.2 2.4 83.3
Area 9 19.9 70.0 13.8 6.1 78.8
Area 10 19.2 19.0 18.7 0.5 100.0
Area 11 17.6 60.5 12.4 5.2 63.2
Area12 17.5 54.5 17.5 0 NA
Area 13 17.3 78.6 15.9 1.4 100.0
Area 14 17.0 39.4 13.4 3.6 57.7
Area 15 15.6 68.2 13.4 2.2 50.0
Area 16 15.5 76.9 14.5 1.0 100.0
Area 17 15.1 75.7 10.2 4.9 81.2
Area 18 15.1 60.0 15.1 0 NA
Area 19 14.3 89.5 13.4 0.9 0
Area 201 14.1 74.1 13.4 0.7 100.0
Area 21 13.4 69.4 11.3 2.1 100.0
Area 22 13.2 25.0 10.6 2.6 0
Area 23 11.8 29.6 10.5 1.3 0
Area 24 10.8 85.7 5.4 5.4 100.0
Area 25 8.7 80.0 7.5 1.2 100.0
Area 26 5.7 66.7 5.7 0 NA
Total 17.6 62.9 13.9 3.7 75.2
NA, not applicable; PCT, Primary Care Trust; SGA, second-generation antipsychotic.
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The key drivers inﬂuencing excessive treatment length
are unclear. No data are published on who initiates anti-
psychotic treatment in LTC in England (eg, hospital clini-
cians or GPs), although there is research on continuation
of treatment. A study in one UK region found that 79% of
residents in 10 care homes who were prescribed risperi-
done or olanzapine were under GP-only care, and moni-
tored only infrequently.13 Similarly, a study of 65 English
care homes identiﬁed infrequent monitoring with only
25% of residents who were prescribed an antipsychotic
receiving a medication review by their GP in the preceding
12 months.4 More recently, a British Geriatrics Society
Inquiry found that continuation of therapy is largely
managed by GPs, with evidence that they may fail to under-
take regular reviews as recommended.56 The excessive
treatment length observed in our cohort may therefore be
associated with a lack of regular review by GPs or commu-
nity pharmacists. An added reason offered for continuation
of antipsychotic treatment in care homes is to reduce dis-
tress of staff.57 58 Against this, there is evidence of wide vari-
ability in distress among care staff exposed to the same
resident behaviour, and poor agreement among senior
staff about which of their residents present with challen-
ging behaviour.59 In fact, research from Denmark indicates
that behavioural problems are a determinant for the use of
antipsychotics, irrespective of the resident’s diagnosis.60
The large variations we observed in antipsychotic use
between care homes may be due to various factors such
as clinical need, stafﬁng levels or broader organisational
factors such as leadership and investment in staff devel-
opment.61 Although we found residents in care homes
registered for dementia were over-represented in our
highest prescribing quintile indicating a link with clin-
ical need, other factors appeared to have a greater
impact. Since we lacked clinical data to complement the
detailed prescription data, these could not be explored
further. However, researchers elsewhere have identiﬁed
that clinical need does not appear to be a key driver
inﬂuencing prescribing rates. A Canadian study which
recorded a threefold variation among 485 nursing
homes found that residents were prescribed antipsycho-
tics irrespective of clinical indication.62 Similarly, for
16 586 newly admitted nursing home residents, a US
study reported that someone entering a home which
exhibits the highest prescribing rate is 1.37 times more
likely to receive antipsychotics, after adjusting for poten-
tial clinical indications, than someone admitted to the
lowest prescribing facilities.2
‘Prescribing culture’ has therefore been suggested as
an important factor inﬂuencing antipsychotic use in
nursing home.2 63–66 In our study, although we could
not measure prescribing culture, residents in homes
served by a single GP practice were more likely to be in
the lowest prescribing quintile, compared with LTC set-
tings with more complex multipractice medical support.
Treatment culture may be inﬂuenced by a more consist-
ent message provided by one practice, with requests to
continue use of antipsychotics addressed more
appropriately. In the multipractice context, where up to
21 GP practices served a single care home, the lack of
consistent messages may emerge, especially important in
residential homes where medication is managed by non-
clinical social care staff that may require more consistent
advice and support.34
Interestingly, our ﬁndings also indicate that residents in
care homes located in deprived neighbourhoods are sig-
niﬁcantly over-represented in the highest prescribing quin-
tile. Although there is no other similar UK research, a US
study of 17 000 care homes has identiﬁed that compared
with ‘not-for-proﬁt’ or government-owned homes, residents
in ‘for-proﬁt’ nursing homes are more likely to be pre-
scribed antipsychotics; this ﬁnding was explained by lower
nurse stafﬁng levels.67 Evidence on a direct relationship
between stafﬁng levels and antipsychotic use is currently
lacking.68 However, a measurable and sustained reduction
in nursing staff burden has been reported in a double-
blind, placebo-controlled randomised controlled trial
(RCT) of risperidone treatment in 279 older nursing
home residents with dementia.69 A more recent RCT has
found that medication also reduces informal carer time by
half but is not cost-effective compared with placebo when
examining the primary clinical outcome of change in
depressive symptoms.70 Although we did not have stafﬁng
details in our study, six homes in the sample were identiﬁed
by the Care Quality Commission (CQC) as having inad-
equate stafﬁng levels,71 and all were located in deprived
neighbourhoods. Placing this in context, the mean annual
expenditure on antipsychotics we observed was £65.60 per
resident. This is <1% of the annual cost of a UK residential
home place for a person with dementia (£32 241).72
Finally, very few studies have examined geographical
variations in prescribing in LTC. A recent survey of US
nursing homes identiﬁed a threefold geographical dif-
ference, with lower antipsychotic prescribing levels in
Hawaii (12.4%) than in Louisiana (33.5%); this was
based on self-reported rates so response bias cannot be
excluded.51 Our study identiﬁed even larger geograph-
ical differences in off-label prescribing and similar varia-
tions in whether the licensed agent was prescribed as
ﬁrst-line therapy. There is no evident reason for this.
The current study presents data from a larger sample
of care homes than other UK studies to date, but there
are a number of limitations. First, a lack of data on care
home characteristics, at a national-level, means that it is
not possible to demonstrate representativeness of the
sample. Because these care homes were early adopters of
the EMM innovation, it could be argued that they might
also be high performers in terms of resident care, leaving
little room for improvement in antipsychotic prescribing
levels. However, the large range we observed in anti-
psychotic use between care homes, and in the types of
antipsychotics prescribed and lengths of treatment,
would seem to contradict this hypothesis. A further limi-
tation was the absence of electronic health records in the
facilities studied, to complement the comprehensive elec-
tronic prescription data and identify all residents with a
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diagnosis of dementia. However, the majority of people
with dementia in the UK did not have a formal diagnosis
during this period,20 so it would have been difﬁcult to
identify such residents conﬁdently using routine data.17
The UK is not unusual, and barriers to the introduction
of electronic health records in long-term care facilities
are recognised internationally.73 Unlike the Barber et al36
study, a lack of clinical data precluded the use of
approaches, such as multilevel modelling, to examine
patient-level data (see online supplementary ﬁle 2).
Finally, although there is a possibility that the NDS may
have had an impact on antipsychotic use in care homes at
the time of its launch with central support, our data
clearly indicate that this was not sustained over time.
Policy and research implications
The NDS was not associated with sustained change in the
use of antipsychotics in people resident in care homes.
The economic burden of dementia in the UK is estimated
to be £4 billion per year, more than cancer, heart disease
and stroke combined.74 Further strategies may be required
to achieve control and reduce the inappropriate use of
antipsychotics in care homes.75 As a ﬁrst step, standards
specifying recommended agents, dosages and length of
treatment would be helpful. Second, consideration should
be given to routine reporting of patterns of prescribing for
care home residents that are subject to regulatory scrutiny;
the NDS did not include long-term monitoring mechan-
isms let alone enforcement mechanisms. Antipsychotic
prescribing patterns in UK care homes are not open to
public scrutiny nor routinely reported by regulatory
inspection. Finally, research is needed to explore why pre-
scribing appears to have been unaffected by the NDS.
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